Bruker winds down underperforming instrument lines


Instrument heavyweight Bruker is winding down its range of stand-alone gas chromatography (GC), inductively-coupled plasma mass spectrometry (ICP-MS) and single quadrupole GC-MS instruments. In a statement, the company said that its Chemical and Applied Markets division, which houses these products, has generated significant losses for the last four years, with little prospect of near-term profitability.

Bruker will honour outstanding orders for the affected GC and GC-MS instruments, but is not taking any new orders. The company is looking to sell off its ICP-MS business, and for someone to take over the service contracts for the GC instruments. The firm will retain support for GC-MS systems, as it continues to sell instruments with triple-quadrupole mass detectors.

At the same time, the company is expanding its microscopy offering in the life sciences, by acquiring US start-up Vutara for its high speed, 3D, super resolution fluorescence microscopy technology. The companies did not disclose financial details of the transaction.


Related Content

X marks the structure

31 October 2014 Review

news image

Elisabeth Jeffries discovers there’s a diffractometer for everything from crystals to proteins

A close look at microscopy

5 November 2013 Review

news image

Elisabeth Jeffries zooms in on scanning probe microscopy and other techniques

Most Read

Flushing advice is flawed

24 August 2015 Research

news image

Protocols to restore contaminated water supplies are not based on science

Simple chemistry saving thousands of gold miners from mercury poisoning

25 August 2015 News and Analysis

news image

Basic apparatus is cutting mercury pollution and helping Indonesian miners go for gold

Most Commented

New drug treatment for alcoholism shows promise in animal studies

24 August 2015 Research

news image

Compounds that target a receptor in the brain appear less addictive with fewer negative side-effects than existing drugs

A risky business

28 August 2015 In the Pipeline

news image

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe